Kancera AB (publ) today comments on the potential for its fractalkine blocking drug candidate KAND567 based on a newly published research publication that summarizes clinical research addressing the pathology driving role of fractalkine axis in cardiovascular disease. KAND567 is...
Read MoreKancera AB (publ) today reports that the first patient in the KANDOVA study, a combined phase Ib/IIa study in ovarian cancer, has been dosed with KAND567.
Read MoreKancera AB (publ) today announces that Peter Selin is appointed as new Chief Executive Officer (CEO) as of July 1 2023. At the same time, Thomas Olin is appointed as Executive Vice President and Chief Scientific Officer (CSO).
Read MoreThe period in briefJanuary – MarchFinancial summary for the first quarter• Net sales amounted to SEK 0 million (SEK 0).• R&D expenses amounted to SEK 15,2 million (SEK10,6 million).• Operating profit for the first quarter amounted to SEK -17.2...
Read MoreKancera today reports that patient screening to the KANDOVA-study, a combined phase Ib/IIa study of the Fractalkine blocker KAND567 in ovarian cancer patients, has been started at the Karolinska University Hospital.
Read MoreKancera today reports that the company has submitted the regulatory application to conduct a First-In-Human study of its Fractalkine blocker KAND145.
Read MoreKancera AB (publ) today reports that the Japan patent office has issued a patent that protects the manufacturing processes for Kancera’s Fractalkine blocking drug candidates KAND567 and KAND145.
Read MoreKancera AB (publ) today reports that the patient enrollment to the ongoing FRACTAL-study, a phase IIa study of KAND567 in myocardial infarction patients, has been completed and that a total of 71 patients have been recruited. Kancera aims to...
Read MoreYear in briefOctober – DecemberFinancial summary for the fourth quarter Net sales amounted to SEK 0 million (SEK 0.0 million). R&D costs amounted to SEK 11,6 million (12,9 million). Operating profit for the fourth quarter amounted to SEK -14,0...
Read MoreKancera AB (publ) today reports that the Swedish Medical Products Agency has approved the application to conduct the KANDOVA-study, a clinical study of KAND567 in ovarian cancer patients. The company further reports organizational changes, including the appointment of a...
Read More